Haemonetics (HAE) EPS (Weighted Average and Diluted) (2009 - 2026)

Haemonetics' EPS (Weighted Average and Diluted) history runs 18 years deep, the most recent figure standing at -$0.41 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) fell 135.04% year-over-year to -$0.41; the TTM figure through Mar 2026 stood at $2.05 (down 38.07% YoY), while the FY2026 annual figure was $2.05, down 38.07% from the prior year.
• EPS (Weighted Average and Diluted) was -$0.41 for Q1 2026 at Haemonetics, down from $0.95 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.17 in Q1 2025 to a low of -$0.41 in Q1 2026.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.58 across 5 years, with a median of $0.64 in 2022.
• The sharpest annual moves came in 2022 and 2026: EPS (Weighted Average and Diluted) surged 522.22% in 2022, then plunged 135.04% in 2026.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.64 in 2022, then retreated by 4.69% to $0.61 in 2023, then advanced by 21.31% to $0.74 in 2024, then grew by 28.38% to $0.95 in 2025, then slumped by 143.16% to -$0.41 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.41 (Q1 2026), $0.95 (Q4 2025), and $0.81 (Q3 2025), per Business Quant data.